Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Marie Skłodowska-Curie Action · Running

POLYTROP Development of Novel Multimodal Dextran-Based Theranostic Tracers: Targeting Fibroblast Activation Protein as Proof of Concept

Coordinator
National Center for Scientific Research ""demokritos"""", Greece
Runs
1 June 2023 to 31 May 2025
Status
Running
EU funding
€169k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101130787

What the project is doing

In the project's own words, from its summary on CORDIS.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 20 million new cases and 10 million deaths in 2020. This project addresses the development of a novel compound targeting the fibroblast activation protein, overexpressed in more than 90% of human epithelial cancers. It combines up to four imaging techniques (single-photon emission computed tomography, positron emission tomography, magnetic resonance, and optical imaging) and two therapeutic approaches (radionuclide therapy and boron neutron capture therapy (BNCT)).

The novel compound is based on a dextran scaffold, which acts as a backbone for attachment of i) a FAP-inhibitor based on a quinoline structure, ii) a macrocycle chelator for complexation with Gadolinium, Technetium-99m, Rhenium-188, Gallium-68, and Lutetium-177 for imagining or radionuclide therapy, iii) carborane for BNCT and iv) fluorescent dye for optical imaging. The aim is to achieve a tailor-made combination of unique and versatile properties by adapting the multifunctional structure of the ligand compound throughout different imaging and therapeutic procedures using a simple and robust labeling protocol, exploiting the outstanding properties of each moiety and conferring our compound with precisely designed functionalities.

The implementation and delivery of high-impact outcomes will be achieved following a well-defined route. The long-term objective of this project is to determine whether vial kits for imaging and therapy can be developed. The novel ligand will be synthesized following well-established methodologies and fully characterized by elemental analysis, IR, and NMR. Then, the radiolabeling procedures of the ligand with the radionuclides will be optimized, and a kit formulation will be developed.

At the same time, the project will determine the inhibitory activities of the radiolabeled compounds and their applicability for in vivo imaging and radionuclide therapy in FAP-positive tumor-bearing mice.

Topics

Who is involved

OrganisationCityCountryRole
National Center for Scientific Research ""demokritos""""Agia ParaskeviGreeceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI